-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $9

Benzinga·05/07/2026 15:00:07
Listen to the news
Wells Fargo analyst Larry Biegelsen maintains RxSight (NASDAQ:RXST) with a Equal-Weight and lowers the price target from $11 to $9.